Physician profile
Stuart A Ort
NPI 1083831325
$3,600.14
in general payments reported to CMS, 2019-2025
30 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $286 · 2021: $467 · 2022: $328 · 2023: $818 · 2024: $541 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $719.67 | 2019-2025 | |
| Inspire Medical Systems, INC. | $677.60 | 2023-2025 | Inspire |
| Genzyme Corporation | $303.81 | 2019-2025 | |
| Csl Behring | $294.47 | 2019-2025 | Hizentra |
| Aerin Medical INC. | $275.36 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $238.15 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $218.75 | 2021-2025 | Nucala |
| Stryker Corporation | $155.94 | 2019-2025 | Xpress Loprofile |
| Cochlear Americas | $82.75 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Takeda Pharmaceuticals U.S.A., INC. | $81.10 | 2020-2025 | Cuvitru |
| Alk-Abello, INC | $72.68 | 2019-2022 | |
| Organogenesis INC. | $56.73 | 2021-2022 | |
| Genentech USA, INC. | $45.83 | 2024-2025 | Xolair |
| Acclarent, INC | $38.91 | 2022 | |
| Octapharma USA, INC. | $38.28 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $28.75 | 2019 | |
| Merck Sharp & Dohme LLC | $28.36 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $27.56 | 2021 | |
| Kaleo, INC. | $27.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.70 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $21.64 | 2025 | Neffy |
| Lilly USA, LLC | $18.26 | 2025 | Zepbound |
| Precigen, INC. | $18.00 | 2025 | Papzimeos |
| Biocryst US Sales Co., LLC | $17.95 | 2025 | Orladeyo |
| Intersect Ent, INC. | $17.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.02 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.66 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.21 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.06 | 2020 | |
| Glenmark Therapeutics INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Ort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.